secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0000950170-25-030407
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma reports FY2024 net loss of $58.7M; cash runway to end of 2026; Phase 2 interim data mid-2025
--------------------------------------------------------------------------------

- Net loss of $58.7M for FY2024, compared to $69.0M in FY2023; no revenue.
- Cash, cash equivalents & marketable securities of $183.3M as of Dec 31, 2024; provides cash runway to end of 2026.
- Phase 2 PYNNACLE trial enrollment on track; interim analysis data expected mid-2025; NDA submission anticipated by end of 2026.
- Discontinued enrollment in Phase 1b combination arm of rezatapopt with pembrolizumab due to lack of clinically meaningful benefit.
- Enrollment commenced in investigator-initiated Phase 1b study of rezatapopt in relapsed/refractory AML/MDS with TP53 Y220C mutation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000095017025030407/0000950170-25-030407-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000095017025030407/pmvp-20250303.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-030407

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer